Seres Therapeutics, Inc. (MCRB)
2.94
+0.01
(+0.34%)
USD |
NASDAQ |
Oct 02, 16:00
2.93
-0.01
(-0.34%)
After-Hours: 20:00
Seres Therapeutics EPS Diluted (Quarterly) : 0.47 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.47 |
| March 31, 2026 | -2.078 |
| December 31, 2025 | -1.605 |
| September 30, 2025 | 0.9353 |
| June 30, 2025 | -2.271 |
| March 31, 2025 | 3.750 |
| December 31, 2024 | -1.808 |
| September 30, 2024 | -0.3795 |
| June 30, 2024 | -4.339 |
| March 31, 2024 | -5.494 |
| December 31, 2023 | -6.382 |
| September 30, 2023 | -7.460 |
| June 30, 2023 | 0.3585 |
| March 31, 2023 | -0.5655 |
| December 31, 2022 | -0.5494 |
| September 30, 2022 | -0.4897 |
| June 30, 2022 | -0.7017 |
| March 31, 2022 | -0.6144 |
| December 31, 2021 | -0.5441 |
| September 30, 2021 | 0.7184 |
| June 30, 2021 | -0.5273 |
| March 31, 2021 | -0.3875 |
| December 31, 2020 | -0.1996 |
| September 30, 2020 | -0.3625 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.2826 |
| March 31, 2020 | -0.2807 |
| December 31, 2019 | -0.2677 |
| September 30, 2019 | -0.2346 |
| June 30, 2019 | -0.2383 |
| March 31, 2019 | -0.5931 |
| December 31, 2018 | -0.52 |
| September 30, 2018 | -0.5379 |
| June 30, 2018 | -0.68 |
| March 31, 2018 | -0.69 |
| December 31, 2017 | -0.7136 |
| September 30, 2017 | -0.17 |
| June 30, 2017 | -13.80 |
| March 31, 2017 | -0.63 |
| December 31, 2016 | -0.63 |
| September 30, 2016 | -0.46 |
| June 30, 2016 | -0.70 |
| March 31, 2016 | -0.50 |
| December 31, 2015 | -0.5024 |
| September 30, 2015 | -0.38 |
| June 30, 2015 | -0.4128 |
| March 31, 2015 | -0.2046 |
| March 31, 2014 | -0.0494 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 4.366 |
| BioCryst Pharmaceuticals, Inc. | 0.2957 |
| Imunon, Inc. | -0.5412 |
| Curis, Inc. | -4.017 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 4.581M |
| Revenue (Quarterly) | 0.736M |
| Total Expenses (Quarterly) | -3.845M |
| Enterprise Value | 69.94M |
| Gross Profit Margin (Quarterly) | 8.97% |
| Earnings Yield | -77.46% |
| Normalized Earnings Yield | -60.53 |